Current Status of siRNA Delivery Technology and siRNA Drug Development
نویسندگان
چکیده
منابع مشابه
Current Status of siRNA Delivery Technology and siRNA Drug Develop- ment
In the past decade, therapeutic potential of RNA interference (RNAi) and its application to human diseases were widely discussed in the related fields of biology, medical sciences, and pharmaceutical sciences. In course of these research and developing processes, efficient transduction of small interfering RNA (siRNA) into target cells is one of the most significant breakthroughs in revealing t...
متن کاملNanolipoparticles-mediated MDR1 siRNA delivery: preparation, characterization and cellular uptake
Objective(s): Lipid-based nanoparticles (NLP) are PEGylated carriers composed of lipids and encapsulated nucleic acids with a diameter less than 100 nm. The presence of PEG in the NLP formulation improves the particle pharmacokinetic behavior. The purpose of this study was to prepare and characterize NLPs containing MDR1 siRNA and evaluate their cytotoxicity and cellular uptake. MDR1 siRNA coul...
متن کاملsiRNA delivery and targeting.
RNA interference (RNAi) is one of the most dramatic findings over the past decade, and the number of publications related to RNAi increased exponentially from 5 in 1998 to more than 2400 in 2008. Generally, RNAi can be achieved by three strategies: chemical synthesized small interfering RNA (siRNA), long double-stranded RNA (dsRNA), and DNA-based (plasmid or viral vector) short hairpin RNA (shR...
متن کاملTargeted Delivery of siRNA
Therapeutic application of siRNA requires delivery to the correct intracellular location, to interact with the RNAi machinery within the target cell, within the target tissue responsible for the pathology. Each of these levels of targeting poses a significant barrier. To overcome these barriers several strategies have been developed, such as chemical modifications of siRNA, viral nucleic acid d...
متن کاملAptamer mediated siRNA delivery
Nucleic acids that bind to cells and are subsequently internalized could prove to be novel delivery reagents. An anti-prostate specific membrane antigen aptamer that has previously been shown to bind to prostate tumor cells was coupled to siRNAs via a modular streptavidin bridge. The resulting conjugates could be simply added onto cells without any further preparation, and were taken up within ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Open Drug Delivery Journal
سال: 2007
ISSN: 1874-1266
DOI: 10.2174/1874126600701010020